These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22162639)

  • 1. Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release.
    Benedek IH; Jobes J; Xiang Q; Fiske WD
    Drug Des Devel Ther; 2011; 5():455-63. PubMed ID: 22162639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tablets.
    Fiske WD; Jobes J; Xiang Q; Chang SC; Benedek IH
    J Pain; 2012 Jan; 13(1):90-9. PubMed ID: 22208805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label pharmacokinetic study of oxymorphone extended release in the presence of naltrexone in the older adult.
    Pergolizzi JV; Raffa RB; Taylor R; Nagar S; Labhsetwar S; Sinclair N; Gould EM
    J Opioid Manag; 2012; 8(6):383-93. PubMed ID: 23264316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study.
    Adams MP; Ahdieh H
    Pharmacotherapy; 2004 Apr; 24(4):468-76. PubMed ID: 15098800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
    Kinzler ER; Pantaleon C; Iverson M; Aigner S
    Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects.
    Kinzler ER; Pantaleon C; Aigner S
    Clin Ther; 2018 Aug; 40(8):1357-1365. PubMed ID: 30049503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, rater-blinded, crossover study of the effects of oxymorphone extended release, fed versus fasting, on cognitive performance as tested with CANTAB in opioid-tolerant subjects.
    Spierings EL; Volkerts ER; Heitland I; Thomson H
    Pain Med; 2014 Feb; 15(2):264-71. PubMed ID: 24330343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence of single and multiple doses of venlafaxine extended-release tablets and capsules in the fasted and fed states: four open-label, randomized crossover trials in healthy volunteers.
    Wright CW; Aikman MS; Werts E; Seabolt J; Haeusler JM
    Clin Ther; 2009 Nov; 31(11):2722-34. PubMed ID: 20110014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users.
    Schoedel KA; McMorn S; Chakraborty B; Potts SL; Zerbe K; Sellers EM
    J Opioid Manag; 2011; 7(3):179-92. PubMed ID: 21823549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets.
    Adams MP; Ahdieh H
    Drugs R D; 2005; 6(2):91-9. PubMed ID: 15777102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic Bioequivalence Studies of an Extended-Release Oxycodone Hydrochloride Tablet in Healthy Japanese Subjects Under Fasting and Fed Conditions Without an Opioid Antagonist.
    Toyama K; Furuie H; Kuroda K; Ishizuka H
    Drugs R D; 2017 Sep; 17(3):363-370. PubMed ID: 28516342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®) and an extended release morphine sulfate capsule formulation (KADIAN®) in healthy adults under fasting conditions.
    Johnson FK; Ciric S; Boudriau S; Kisicki JC; Stauffer J
    Am J Ther; 2011 Jan; 18(1):2-8. PubMed ID: 20864883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P; Könen-Bergmann M; Schepers C; Haertter S
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects.
    Darwish M; Bond M; Tracewell W; Robertson P; Yang R
    Clin Drug Investig; 2015 Jan; 35(1):13-22. PubMed ID: 25391549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers.
    Estevez-Carrizo FE; Parrillo S; Ercoli MC; Estevez-Parrillo FT
    Clin Ther; 2011 Jun; 33(6):738-45. PubMed ID: 21704238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
    Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Food on the Pharmacokinetics of Single- and Multiple-Dose Hydrocodone Extended Release in Healthy Subjects.
    Bond M; Rabinovich-Guilatt L; Selim S; Darwish M; Tracewell W; Robertson P; Yang R; Malamut R; Colucci P; Ducharme MP; Spiegelstein O
    Clin Drug Investig; 2017 Dec; 37(12):1153-1163. PubMed ID: 28948482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.